{"date":"2026-01-14","count":15,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4123-2026-01-14-2332-xx5k5t","company_id":"4123","company":"晟德","market":"上櫃","industry":"生技醫療","date":"2026-01-14","time":"23:32:52","subject":"本公司及子公司玉晟管理顧問擬就所持東曜藥業股份之潛在全面公開收購案出具不可撤回承諾，並依約出售股份","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晟德（4123），2026-01-14 23:32，「本公司及子公司玉晟管理顧問擬就所持東曜藥業股份之潛在全面公開收購案出具不可撤回承諾，並依約出售股份」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6586-2026-01-14-2051-892spo","company_id":"6586","company":"醣基","market":"興櫃","industry":"生技醫療","date":"2026-01-14","time":"20:51:24","subject":"本公司研發之醣抗原抗體抗癌新藥(簡稱:CHO-A04)向台灣衛福部食品藥物管理署(TFDA)提出人體臨床試驗審查申請(IND)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：醣基（6586），2026-01-14 20:51，「本公司研發之醣抗原抗體抗癌新藥(簡稱:CHO-A04)向台灣衛福部食品藥物管理署(TFDA)提出人體臨床試驗審查申請(I」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2026-01-14-1805-1ap8fql","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2026-01-14","time":"18:05:29","subject":"公告本公司註銷收回之限制員工權利新股辦理減資變更登記完成","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：美時（1795），2026-01-14 18:05，「公告本公司註銷收回之限制員工權利新股辦理減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6885-2026-01-14-1752-19b096m","company_id":"6885","company":"全福生技","market":"上市","industry":"生技醫療","date":"2026-01-14","time":"17:52:13","subject":"公告本公司開發中新藥BRM411治療青光眼第I/IIb期人體臨床試驗已獲數據安全監督委員會（DSMB）正面回應，確定第I期安全性無虞，並於今日完成第IIb期首位受試者收案。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：全福生技（6885），2026-01-14 17:52，「公告本公司開發中新藥BRM411治療青光眼第I/IIb期人體臨床試驗已獲數據安全監督委員會（DSMB）正面回應，確定第I」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4178-2026-01-14-1747-a6l8wf","company_id":"4178","company":"永笙-KY","market":"上市","industry":"生技醫療","date":"2026-01-14","time":"17:47:17","subject":"公告本公司董事會決議召開115年第一次股東臨時會事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：永笙-KY（4178），2026-01-14 17:47，「公告本公司董事會決議召開115年第一次股東臨時會事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-5312-2026-01-14-1735-1roellr","company_id":"5312","company":"寶島科","market":"上櫃","industry":"生技醫療","date":"2026-01-14","time":"17:35:41","subject":"公告本公司董事辭任","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：寶島科（5312），2026-01-14 17:35，「公告本公司董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2026-01-14-1651-gnfxub","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2026-01-14","time":"16:51:55","subject":"公告本公司「封閉型細胞分離操作裝置」取得英國發明專利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2026-01-14 16:51，「公告本公司「封閉型細胞分離操作裝置」取得英國發明專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-01-14-1625-11onx11","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-01-14","time":"16:25:12","subject":"公告本公司與Cyto-Facto Inc.簽署合作意向書（LOI），規劃評估進行CDMO委託開發與製造服務合作。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-01-14 16:25，「公告本公司與Cyto-Facto Inc.簽署合作意向書（LOI），規劃評估進行CDMO委託開發與製造服務合作。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6864-2026-01-14-1505-1ea9cvn","company_id":"6864","company":"元樟生技","market":"興櫃","industry":"生技醫療","date":"2026-01-14","time":"15:05:12","subject":"公告本公司新增協辦推薦證券商事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：元樟生技（6864），2026-01-14 15:05，「公告本公司新增協辦推薦證券商事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6733-2026-01-14-1432-1bj9ow8","company_id":"6733","company":"博晟生醫","market":"上櫃","industry":"生技醫療","date":"2026-01-14","time":"14:32:00","subject":"公告本公司114年現金增資發行新股認股基準日等相關事宜(更正現金增資認股基準日)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：博晟生醫（6733），2026-01-14 14:32，「公告本公司114年現金增資發行新股認股基準日等相關事宜(更正現金增資認股基準日)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2026-01-14-1337-li9lxd","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2026-01-14","time":"13:37:42","subject":"子公司新增資金貸與符合資金貸與及背書保證處理準則第22條第1項第3款情事","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2026-01-14 13:37，「子公司新增資金貸與符合資金貸與及背書保證處理準則第22條第1項第3款情事」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2026-01-14-1337-xbx7im","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2026-01-14","time":"13:37:11","subject":"本公司董事會決議買回庫藏股","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2026-01-14 13:37，「本公司董事會決議買回庫藏股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2026-01-14-1336-4ij7s0","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2026-01-14","time":"13:36:10","subject":"本公司董事會決議114年股東常會通過之私募現金增資發行普通股案不繼續辦理","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2026-01-14 13:36，「本公司董事會決議114年股東常會通過之私募現金增資發行普通股案不繼續辦理」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6934-2026-01-14-1227-qkrt5g","company_id":"6934","company":"心誠鎂","market":"上市","industry":"生技醫療","date":"2026-01-14","time":"12:27:31","subject":"公告本公司股務代理機構名稱、辦公處所及聯絡電話","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：心誠鎂（6934），2026-01-14 12:27，「公告本公司股務代理機構名稱、辦公處所及聯絡電話」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-01-14-0603-vq1u7e","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-01-14","time":"06:03:16","subject":"本公司代子公司思捷優達股份有限公司公告開發中新藥YA-101獲歐盟EMA授予用於治療多重系統退化症之孤兒藥資格認定。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-01-14 06:03，「本公司代子公司思捷優達股份有限公司公告開發中新藥YA-101獲歐盟EMA授予用於治療多重系統退化症之孤兒藥資格認定。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}